Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 8/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5652450 | 0.88 | KCNH2 (0.54) | KCNH2DRD2DRD4SLC2A1HTR1A | |
| SCHEMBL5650170 | 0.86 | KCNH2 (0.68) | KCNH2SLC2A1 | |
| SCHEMBL3693230 | 0.86 | KCNH2 (0.68) | KCNH2SLC2A1 | |
| SCHEMBL5254892 | 0.83 | KCNH2 (0.74) | KCNH2DRD2DRD4SLC2A1 | |
| SCHEMBL5251668 | 0.83 | KCNH2 (0.74) | KCNH2DRD2DRD4SLC2A1 | |
| SCHEMBL3690676 | 0.82 | KCNH2 (0.51) | KCNH2SLC2A1 | |
| SCHEMBL3694049 | 0.81 | KCNH2 (0.58) | KCNH2SLC2A1 | |
| SCHEMBL3690390 | 0.79 | KCNH2 (0.47) | KCNH2DRD2DRD4HTR1A | |
| SCHEMBL5433187 | 0.78 | HTR1A (0.48) | KCNH2DRD2DRD4PARP1HTR1A | |
| SCHEMBL3691874 | 0.77 | KCNH2 (0.66) | KCNH2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2239260-A1 | Novel compounds with antibacterial activity | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2010-10-13 | — | — | EP | disclosed |
| US-7223776-B2 | Compounds with anti-bacterial activity | MORPHOCHEM AG (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20060040949-A1 | Novel compounds with antibacterial activity | MORPHOCHEM AG | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040949-A1 | Novel compounds with antibacterial activity | MRPL21, Q6ZSR9, MRPL19 | KCNH2 2411/4885DRD2 4147/4885DRD4 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.